Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.
With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.
Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.
Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.
Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.
For more information, visit www.bauschhealth.com.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has finalized the sale of its equity interests in Amoun Pharmaceutical Company to Abu Dhabi-based ADQ, yielding approximately $740 million, subject to adjustments. This strategic move is set to allow Bausch Health to reduce its overall debt. CEO Joseph C. Papa emphasized the company's commitment to enhancing shareholder value and preparing for the planned spinoff of Bausch + Lomb. The transaction follows a definitive agreement made earlier in March 2021.
Bausch Health Companies (NYSE/TSX: BHC) announced the recipients of its 2021 Aspire Higher scholarship program, awarding scholarships of up to $10,000 to nine students affected by dermatologic conditions. This initiative aims to support these students in achieving their academic goals. Since its inception in 2012, the program has awarded $648,000 in total. The chosen recipients were selected from nearly 150 applications based on their personal essays. The program recognizes a diverse range of educational pursuits across various scholarship categories.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the winners of its 2021 Salix Gastrointestinal Health Scholars Program, awarding $100,000 in scholarships to ten students with gastrointestinal (GI) diseases. Each recipient will receive $10,000 to support their higher education goals. The competitive selection process considered over 150 applications, highlighting the personal challenges faced by students due to their GI conditions. Salix Pharmaceuticals aims to assist these students in overcoming educational hurdles, reflecting the company’s commitment to improving the lives of those living with GI diseases.
Bausch + Lomb, part of Bausch Health Companies (NYSE/TSX: BHC), will present 14 scientific posters on its ophthalmic surgical technologies at the American Society of Cataract and Refractive Surgery annual meeting from July 23-27, 2021, in Las Vegas. These presentations cover key areas such as the clinical performance of IOL platforms and the impact of COVID-19 on surgeries. The event marks a significant return to in-person scientific exchanges, emphasizing the company's commitment to research and improved patient outcomes.
Bausch Health Companies (NYSE/TSX: BHC) announces the U.S. launch of Biotrue® Hydration Boost Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes designed for dry, irritated eyes. These products are preservative-free, pH-balanced, and utilize naturally inspired ingredients to provide instant relief. They will be available at major retailers like Walgreens and CVS, with a suggested price starting at $11.99. This launch responds to an increasing need for eye care products in the context of rising digital device usage.
Bausch Health Companies (BHC) and Novaliq GmbH have completed enrollment for the second Phase 3 study (MOJAVE) of the investigational drug NOV03, aimed at treating dry eye disease due to meibomian gland dysfunction, involving 622 participants. The drug, if approved, could become a first-in-class treatment. A New Drug Application is planned for submission to the FDA in 2022. Previous Phase 3 trials showed statistically significant results, and ongoing studies aim to reaffirm these findings.
Bausch Health Companies Inc. (NYSE/TSX: BHC) will announce its second-quarter 2021 financial results on August 3, 2021. A conference call and live web cast will be held at 8:00 a.m. EDT to discuss these results, along with a business update. All relevant materials will be available on the company's Investor Relations webpage before the call. Bausch Health focuses on improving lives through its pharmaceutical, medical device, and over-the-counter products primarily in eye health, gastroenterology, and dermatology.
Bausch Health Companies (NYSE/TSX: BHC) announced a significant debt reduction of $150 million by redeeming its 6.125% Senior Notes due in 2025. This redemption, effective August 2, 2021, will bring the total debt redeemed in 2021 to $650 million, utilizing cash generated from operations. The company aims to strengthen its balance sheet and enhance financial flexibility. Bausch Health is committed to advancing healthcare through its diverse range of pharmaceutical products.
Bausch + Lomb, a unit of Bausch Health Companies (NYSE: BHC), announced the U.S. launch of expanded parameters for the Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses. The addition of -2.25D and -2.75D cylinder power increases options for the 32 million people in the U.S. with both astigmatism and presbyopia. This enhancement aims to address the challenges eye care professionals face when fitting these patients, promising improved comfort and visual clarity.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has extended the expiration date for its cash tender offer to purchase all outstanding 7.00% Senior Secured Notes due 2024 by one business day to June 22, 2021, due to the Juneteenth holiday. The Tender Offer commenced on May 24, 2021, and aims to facilitate the purchase of the Notes as outlined in the Offer to Purchase dated May 24, 2021. Goldman Sachs & Co. LLC is the dealer manager for this Tender Offer, providing assistance to holders of the Notes.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
What are the primary areas of focus for Bausch Health?
How many employees does Bausch Health have?
In how many countries does Bausch Health operate?
What is Bausch Health's largest revenue-generating segment?
What recent product development has Bausch Health achieved?
What financial performance did Bausch Health report for Q1 2024?
How is Bausch Health protecting its intellectual property?
Where can I find more information about Bausch Health?
What recent public drug plan listings has Bausch Health achieved in Canada?
Who is the brand ambassador for the XIFAXAN® awareness campaign?
